Search alternatives:
point decrease » point increase (Expand Search)
fold decrease » fold increase (Expand Search), fold increased (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
point decrease » point increase (Expand Search)
fold decrease » fold increase (Expand Search), fold increased (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
15601
-
15602
<i>MMP-1</i> OE restores <i>5HT</i><sub><i>2A</i></sub><i>R</i>-deficient experience-dependent pruning.
Published 2025“…<p><b>A</b>, Or42a OSN innervation of VM7 glomeruli shown as a color-coded Z-stack (scale, top right) with 24-hour exposure from 0 to 1 dpe to the mineral oil vehicle control (<u>left</u>) and EB odorant (<u>right</u>) in astrocyte-like glia control (<u>top</u>: <i>w</i><sup><i>1118</i></sup>;<i> Or42a-mCD8::GFP/+; GMR86E01-Gal4/+</i>), the astrocyte-like glia <i>5-HT</i><sub><i>2A</i></sub><i>R</i> RNAi alone (<u>middle</u>: <i>w</i><sup><i>1118</i></sup>;<i>Or42a-mCD8::GFP/+; GMR86E01-Gal4/UAS-5-HT</i><sub><i>2A</i></sub><i>R RNAi</i>), and with <i>MMP-1</i> overexpression (<u>bottom</u>: <i>w</i><sup><i>1118</i></sup>;<i>Or42a-mCD8::GFP/UAS-MMP1; GMR86E01-Gal4/UAS-5-HT</i><sub><i>2A</i></sub><i>R RNAi</i>). …”
-
15603
-
15604
-
15605
-
15606
-
15607
-
15608
-
15609
-
15610
-
15611
-
15612
-
15613
Knockdown of Esrp1 in E14 ES cells using short hairpin RNA.
Published 2013“…F. qRT-PCR analysis shows an increase in (i) FGFR2 IIIc/IIIb ratio and (ii) Slug, Snai1 and Vimentin in Esrp1-depleted ES cells compared to Scr controls (n = 4). A slight decrease in E-cadherin (E-cad) was also observed. …”
-
15614
Table_1_Risk factors for severe COVID-19 in people with cystic fibrosis: A systematic review.DOCX
Published 2022“…No solid data regarding specific SARS-CoV-2 therapies in patients with CF emerged.</p>Conclusion<p>Most people with CF experience a mild course of SARS-CoV-2 infection, nevertheless subgroups with higher risk of severe outcome emerged. …”
-
15615
-
15616
-
15617
-
15618
-
15619
-
15620